Cholic Acid

- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI ® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia. Cholestatic liver diseases are characterized by impaired bile flow, resulting in elevated serum bile acids, severe pruritus, and significantly reduced quality of life. While LIVMARLI is approved in the United States and European Union for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), patients with other rare cholestatic liver diseases continue to experience debilitating itch and treatment options remain limited. “Completing enrollment in EXPAND marks an important milestone in our efforts to broaden the reach of LIVMARLI to additional patients living with cholestatic pruritus,” said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. “Itch due to cholestasis profoundly affects the daily lives of patients and their families. We aim to address the unmet medical needs of these patients by leveraging our established IBAT mechanism.” The EXPAND study enrolled patients with cholestatic pruritus associated with a range of rare cholestatic liver diseases. In the 20-week placebo-controlled portion, patients are randomized to receive maralixibat 285 micrograms per kilogram (µg/kg) twice daily or placebo. The primary endpoint is change in pruritus severity from baseline to Week 20. Secondary endpoints include changes in serum bile acids and other markers of cholestatic liver disease. “For the patients and families living with rare liver diseases, cholestatic pruritus isn’t just an itch—it can be relentless, exhausting, and life-altering,” said Dr. Mercedes Martinez, M.D., Professor of Pediatrics and Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons. “Yet for many of these conditions, there are still no approved treatment options for pruritus. The EXPAND study marks an important milestone in exploring whether a targeted therapy like LIVMARLI can offer meaningful relief to patients who urgently need better treatment options.” “Families affected by biliary atresia and other rare cholestatic conditions understand the relentless burden of itch,” said Jen Lau, MPH, Co-Founder and Executive Director of BARE, Inc. (Biliary Atresia Research and Education). “The completion of enrollment in EXPAND brings hope that more patients may soon have access to a much-needed treatment option.” Topline data from the EXPAND study are expected in the fourth quarter of 2026. About the EXPAND Phase 3 Study EXPAND is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of LIVMARLI ® (maralixibat) in children aged 6 months and older and adults with cholestatic pruritus associated with rare cholestatic liver diseases. These diseases include biliary atresia and other rare conditions for which LIVMARLI is not currently approved. The primary endpoint is change in pruritus severity from baseline to Week 20. Secondary endpoints include changes in serum bile acids and other markers of cholestatic liver disease. About LIVMARLI ® (maralixibat) oral solution and LIVMARLI ® (maralixibat) tablets LIVMARLI® (maralixibat) is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for two pediatric cholestatic liver diseases. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI.com . LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for the treatment of ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website. IMPORTANT SAFETY INFORMATION Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein. LIVMARLI can cause side effects, including: Liver injury. Changes in certain liver tests are common in patients with ALGS and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal. Stomach and intestinal (gastrointestinal) problems . LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you. A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with ALGS and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects. US Prescribing Information EU SmPC Canadian Product Monograph About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI ® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM ® (cholic acid) for bile-acid synthesis disorders, and CTEXLI ® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at and follow Mirum on Facebook , LinkedIn , Instagram and X . Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, LIVMARLI ® (maralixibat) efficacy in additional patients living with cholestatic pruritus, Mirum’s leadership in rare disease, expectations regarding LIVMARLI ® (maralixibat) ongoing development, including the potential completion of and successful results from the EXPAND trial, the anticipated timing for data from the EXPAND study, and any potential regulatory submission. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expected,” “will,” “could,” “would,” “potential,” “continue,” “plans,” “intended,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized; risk and uncertainties arising from the integration of an acquired company, its employees and its assets with Mirum’s business; risks associated with evaluating companies and assets for acquisition, including that the perceived benefits of the acquisition are not realized; risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies and the potential that estimated prevalences are materially inaccurate; the risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at . All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Contacts Investor Contact: Andrew McKibben ir@mirumpharma.com Media Contact: Meredith Kiernan Media@mirumpharma.com

- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum’s U.S. BLA submission for brelovitug, which has received Breakthrough Therapy designation from the FDA for the treatment of chronic HDV infection. Brelovitug is being developed for HDV, the most severe form of viral hepatitis, and a disease with no approved therapies in the U.S. HDV occurs in people already infected with hepatitis B virus (HBV) and is associated with rapid progression to liver fibrosis, cirrhosis, liver cancer, and liver-related death. “The completion of AZURE-1 enrollment and AZURE-4 screening represent important execution milestones as we advance brelovitug through the Phase 3 AZURE program,” said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. “We look forward to reporting interim data from AZURE-1 in the second quarter and topline results from AZURE-1 and AZURE-4 in the second half of 2026. Both studies are evaluating a composite endpoint of virologic response and ALT normalization at 24 weeks, aligned with FDA guidance for accelerated approval in HDV, and building on the strong antiviral activity observed in our Phase 2 study.” “HDV is an aggressive disease that progresses quickly and leaves patients with very limited treatment options,” said Tatyana Kushner, M.D., MSCE, Associate Professor of Medicine, Division of Gastroenterology and Hepatology at Weill Cornell Medicine. “Having a well-tolerated single-agent therapy that achieves viral suppression and improves liver inflammation is critical for patients with HDV, and the progress of these Phase 3 studies brings us closer to potentially delivering a new therapy to patients in urgent need.” Topline data from AZURE-1 and AZURE-4 are expected in 2H 2026, with a potential BLA submission and launch in the U.S. in 2027. About Brelovitug Brelovitug is an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the chronic hepatitis delta virus (HDV) and the hepatitis B virus (HBV). Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles. Brelovitug has FDA Breakthrough Therapy designation for the treatment of chronic HDV infection and PRIME and Orphan designations from the European Medicines Agency. In the Phase 2 study, brelovitug demonstrated strong antiviral activity in HDV, achieving a 100% HDV RNA response, along with improvements in liver enzyme levels and a favorable safety profile, with the most common adverse event being injection-site erythema. Mirum owns worldwide rights to brelovitug. About the AZURE Clinical Program The AZURE program is a global, registrational Phase 3 clinical development program evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). The program includes multiple open-label studies designed to assess the primary endpoint of combined virologic and biochemical response. Together, the studies are intended to support regulatory filings in the United States and Europe. About AZURE-1 and AZURE-4 AZURE-1 and AZURE-4 are Phase 3 studies that form the basis of Mirum’s U.S. FDA BLA submission for brelovitug in chronic hepatitis delta virus (HDV). AZURE-1 is evaluating approximately 200 treatment-naïve patients randomized in a 2:2:1 ratio to receive brelovitug 300 mg once weekly, brelovitug 900 mg once monthly, or 24-week delayed therapeutic start. AZURE-4 is evaluating approximately 80 treatment-naïve patients randomized in a 2:1:1 ratio to receive brelovitug 300 mg once weekly, brelovitug 900 mg once monthly, or 12-week delayed therapeutic start. Patients randomized to delayed treatment initiate brelovitug 300 mg once weekly upon completion of the treatment delay in both studies. AZURE-4 is being conducted in partnership with PSI CRO. The primary endpoint for both studies is the proportion of patients achieving combined virologic response and ALT normalization at Week 24, consistent with FDA guidance for accelerated approval in HDV. Both studies include open-label extension periods of up to 96 weeks. About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at and follow Mirum on Facebook , LinkedIn , Instagram and X . Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected timing of topline data for the AZURE studies or BLA submission, the quality of data to be submitted for a brelovitug BLA application in the US, the relationship of antiviral activity as an important endpoint in HDV and the success or approval of any potential regulatory submission for brelovitug. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expected,” “will,” “could,” “would,” “potential,” “continue,” “plans,” “intended,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized; risk and uncertainties arising from the integration of an acquired company, its employees and its assets with Mirum’s business; risks associated with evaluating companies and assets for acquisition, including that the perceived benefits of the acquisition are not realized; risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies and the potential that estimated prevalences are materially inaccurate; the risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at . All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Contacts Investor Contact: Andrew McKibben ir@mirumpharma.com Media Contact: Meredith Kiernan Media@mirumpharma.com